184 related articles for article (PubMed ID: 36662602)
41. Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel.
Cartron G; Fox CP; Liu FF; Kostic A; Hasskarl J; Li D; Bonner A; Zhang Y; Maloney DG; Kuruvilla J
Exp Hematol Oncol; 2022 Mar; 11(1):17. PubMed ID: 35337365
[TBL] [Abstract][Full Text] [Related]
42. Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
Perales MA; Anderson LD; Jain T; Kenderian SS; Oluwole OO; Shah GL; Svoboda J; Hamadani M
Transplant Cell Ther; 2022 Sep; 28(9):546-559. PubMed ID: 35768052
[TBL] [Abstract][Full Text] [Related]
43. Safety and Toxicity Profiles of CAR T Cell Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.
Yamshon S; Gribbin C; Alhomoud M; Chokr N; Chen Z; Demetres M; Pasciolla M; Leonard J; Shore T; Martin P
Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):e235-e256.e2. PubMed ID: 38582666
[TBL] [Abstract][Full Text] [Related]
44. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
Halford Z; Anderson MK; Bennett LL
Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
[TBL] [Abstract][Full Text] [Related]
45. Cost-effectiveness analysis of transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma treatment options-Experience of the efficiency frontier approach.
Kurte MS; Siefen AC; Jakobs F; von Tresckow B; Reinhardt HC; Kron F
Eur J Haematol; 2023 Dec; 111(6):895-908. PubMed ID: 37644352
[TBL] [Abstract][Full Text] [Related]
46. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial.
Abramson JS; Siddiqi T; Garcia J; Dehner C; Kim Y; Nguyen A; Snyder S; McGarvey N; Gitlin M; Pelletier C; Jun MP
Blood Adv; 2021 Mar; 5(6):1695-1705. PubMed ID: 33720336
[TBL] [Abstract][Full Text] [Related]
47. Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study.
Wang M; Siddiqi T; Gordon LI; Kamdar M; Lunning M; Hirayama AV; Abramson JS; Arnason J; Ghosh N; Mehta A; Andreadis C; Solomon SR; Kostic A; Dehner C; Espinola R; Peng L; Ogasawara K; Chattin A; Eliason L; Palomba ML
J Clin Oncol; 2024 Apr; 42(10):1146-1157. PubMed ID: 38072625
[TBL] [Abstract][Full Text] [Related]
48. Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature.
Asghar N; Masood A; Dhaliwal A; Khurana S; Davis J; Hashmi H; Husnain M
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):15-21. PubMed ID: 36328891
[TBL] [Abstract][Full Text] [Related]
49. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
50. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
51. Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials.
Palomba ML; Jun MP; Lymp J; Nguyen A; McGarvey N; Gitlin M; Pelletier C; Keating SJ; Godwin J
Leuk Lymphoma; 2021 Sep; 62(9):2169-2176. PubMed ID: 34018458
[TBL] [Abstract][Full Text] [Related]
52. Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed/refractory central nervous system lymphoma: a multicenter retrospective analysis of patients in China.
Yu W; Huang L; Mei H; Li Y; Niu T; Zou D; Liu Y; Zhang H; Liu P; Wu J; Wang Z; Li H; Cai Q; Mi JQ
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38802271
[TBL] [Abstract][Full Text] [Related]
53. Emerging Role of Autologous CD19 CAR T-Cell Therapies in the Second-Line Setting for Large B-cell Lymphoma: A Game Changer?
Mohty R; Moustafa MA; Aljurf M; Murthy H; Kharfan-Dabaja MA
Hematol Oncol Stem Cell Ther; 2022 Nov; 15(3):73-80. PubMed ID: 36395495
[TBL] [Abstract][Full Text] [Related]
54. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.
Morschhauser F; Dahiya S; Palomba ML; Martin Garcia-Sancho A; Reguera Ortega JL; Kuruvilla J; Jäger U; Cartron G; Izutsu K; Dreyling M; Kahl B; Ghesquieres H; Ardeshna K; Goto H; Barbui AM; Abramson JS; Borchmann P; Fleury I; Mielke S; Skarbnik A; de Vos S; Kamdar M; Karmali R; Viardot A; Farazi T; Fasan O; Lymp J; Vedal M; Nishii R; Avilion A; Papuga J; Kumar J; Nastoupil LJ
Nat Med; 2024 Jun; ():. PubMed ID: 38830991
[TBL] [Abstract][Full Text] [Related]
55. Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen.
Abramson JS; Solomon SR; Arnason J; Johnston PB; Glass B; Bachanova V; Ibrahimi S; Mielke S; Mutsaers P; Hernandez-Ilizaliturri F; Izutsu K; Morschhauser F; Lunning M; Crotta A; Montheard S; Previtali A; Ogasawara K; Kamdar M
Future Oncol; 2024 Mar; ():1-11. PubMed ID: 38547003
[TBL] [Abstract][Full Text] [Related]
56. Patient selection for chimeric antigen receptor (CAR) T-cell therapy for aggressive B-cell non-Hodgkin lymphomas.
Johnson PC; Abramson JS
Leuk Lymphoma; 2020 Nov; 61(11):2561-2567. PubMed ID: 32611216
[TBL] [Abstract][Full Text] [Related]
57. Real-World Eligibility for Second-Line Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma: A Population-Based Analysis.
Puckrin R; Stewart DA; Shafey M
Transplant Cell Ther; 2022 Apr; 28(4):218.e1-218.e4. PubMed ID: 35123117
[TBL] [Abstract][Full Text] [Related]
58. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
Locke FL; Miklos DB; Jacobson CA; Perales MA; Kersten MJ; Oluwole OO; Ghobadi A; Rapoport AP; McGuirk J; Pagel JM; Muñoz J; Farooq U; van Meerten T; Reagan PM; Sureda A; Flinn IW; Vandenberghe P; Song KW; Dickinson M; Minnema MC; Riedell PA; Leslie LA; Chaganti S; Yang Y; Filosto S; Shah J; Schupp M; To C; Cheng P; Gordon LI; Westin JR;
N Engl J Med; 2022 Feb; 386(7):640-654. PubMed ID: 34891224
[TBL] [Abstract][Full Text] [Related]
59. Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience.
Casadei B; Argnani L; Guadagnuolo S; Pellegrini C; Stefoni V; Broccoli A; Nanni L; Morigi A; Lolli G; Guarino M; Spinardi L; Pierucci E; Fanti S; Bartoletti M; Dicataldo M; Sabattini E; Bonifazi F; Zinzani PL
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638273
[TBL] [Abstract][Full Text] [Related]
60. A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience.
Kuhnl A; Roddie C; Kirkwood AA; Tholouli E; Menne T; Patel A; Besley C; Chaganti S; Sanderson R; O'Reilly M; Norman J; Osborne W; Bloor A; Lugthart S; Malladi R; Patten PEM; Neill L; Martinez-Cibrian N; Kennedy H; Phillips EH; Jones C; Sharplin K; El-Sharkawi D; Latif AL; Mathew A; Uttenthal B; Stewart O; Marzolini MAV; Townsend W; Cwynarski K; Ardeshna K; Ardavan A; Robinson K; Pagliuca A; Collins GP; Johnson R; McMillan A
Br J Haematol; 2022 Aug; 198(3):492-502. PubMed ID: 35485402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]